多发性骨髓瘤中粒细胞样髓源性抑制细胞的免疫基因组学鉴定与表征
研究旨在基于预后意义、免疫抑制潜力和分子程序为多发性骨髓瘤(MM)中的粒细胞样髓源性抑制细胞(G-MDSC)提供表型谱。预先设定的G-MDSC表型在骨髓样本中与常见嗜酸性粒细胞和中性粒细胞重叠且未在MM患者中扩增,故采用自动化聚类无偏识别粒细胞亚群;在267例新诊断MM患者中,仅成熟中性粒细胞频率与结局显著相关,高成熟中性粒细胞/T细胞比值导致更差的无进展生存(P < .001);成熟中性粒细胞存在时T细胞增殖下降(0.5倍;P = .016),耗竭成熟中性粒细胞后BCMA×CD3双特异性抗体介导的T细胞毒性潜力显著增加(4倍;P = .0007);RNA测序显示G-MDSC相关基因在MM患者成熟中性粒细胞中因差异染色质可及性而特异性上调,首次提供CD11b/CD13/CD16作为准确监测G-MDSC的最佳标志物。
要点
- 在267例新诊断MM患者中,仅诊断时成熟中性粒细胞频率与患者结局显著相关。
- 高成熟中性粒细胞/T细胞比值导致更差的无进展生存(P < .001)。
- 成熟中性粒细胞存在时T细胞增殖下降(0.5倍;P = .016)。
核心结论
- 结果建立了明确定义的中性粒细胞亚群在临床意义、免疫抑制潜力和转录网络之间的关联,首次为准确监测MM中的G-MDSC提供了一组最佳标志物(CD11b/CD13/CD16)。
研究设计与样本
- 使用多维流式细胞术评估对照组和MM患者骨髓样本中预先设定的G-MDSC表型。
- 采用自动化聚类无偏识别肿瘤微环境中所有粒细胞亚群:嗜碱性粒细胞、嗜酸性粒细胞以及未成熟、中间和成熟中性粒细胞。
- 在267例新诊断MM患者(GEM2012MENOS65试验)中分析各亚群频率与患者结局的关联。
- 对每个中性粒细胞亚群进行荧光激活细胞分选,评估T细胞增殖和BCMA×CD3双特异性抗体介导的T细胞毒性潜力。
- 对3个亚群进行RNA测序,比较MM患者与对照组成熟中性粒细胞中G-MDSC相关基因表达及染色质可及性。
主要发现
- 预先设定的G-MDSC表型CD11b+CD14-CD15+CD33+HLADR-细胞与常见嗜酸性粒细胞和中性粒细胞重叠,且未在MM患者中扩增。
- 在267例新诊断MM患者中,仅诊断时成熟中性粒细胞频率与患者结局显著相关,高成熟中性粒细胞/T细胞比值导致更差的无进展生存(P < .001)。
- 成熟中性粒细胞存在时T细胞增殖下降(0.5倍;P = .016)。
- 耗竭成熟中性粒细胞后,BCMA×CD3双特异性抗体介导的T细胞毒性潜力显著增加(4倍;P = .0007)。
- RNA测序显示G-MDSC相关基因在MM患者成熟中性粒细胞中较对照组特异性上调,归因于差异染色质可及性。
关键数值与推荐
- 高成熟中性粒细胞/T细胞比值导致更差的无进展生存(P < .001)。
- 成熟中性粒细胞存在时T细胞增殖下降(0.5倍;P = .016)。
- 耗竭成熟中性粒细胞后BCMA×CD3双特异性抗体介导的T细胞毒性潜力增加(4倍;P = .0007)。
- 首次提供CD11b/CD13/CD16作为准确监测MM中G-MDSC的最佳标志物。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Granulocytic myeloid-derived suppressor cells (G-MDSCs) promote tumor growth and immunosuppression in multiple myeloma (MM). However, their phenotype is not well established for accurate monitoring or clinical translation. We aimed to provide the phenotypic profile of G-MDSCs based on their prognostic significance in MM, immunosuppressive potential, and molecular program. The preestablished phenotype of G-MDSCs was evaluated in bone marrow samples from controls and MM patients using multidimensional flow cytometry; surprisingly, we found that CD11b+CD14-CD15+CD33+HLADR- cells overlapped with common eosinophils and neutrophils, which were not expanded in MM patients. Therefore, we relied on automated clustering to unbiasedly identify all granulocytic subsets in the tumor microenvironment: basophils, eosinophils, and immature, intermediate, and mature neutrophils. In a series of 267 newly diagnosed MM patients (GEM2012MENOS65 trial), only the frequency of mature neutrophils at diagnosis was significantly associated with patient outcome, and a high mature neutrophil/T-cell ratio resulted in inferior progression-free survival (P < .001). Upon fluorescence-activated cell sorting of each neutrophil subset, T-cell proliferation decreased in the presence of mature neutrophils (0.5-fold; P = .016), and the cytotoxic potential of T cells engaged by a BCMA×CD3-bispecific antibody increased notably with the depletion of mature neutrophils (fourfold; P = .0007). Most interestingly, RNA sequencing of the 3 subsets revealed that G-MDSC-related genes were specifically upregulated in mature neutrophils from MM patients vs controls because of differential chromatin accessibility. Taken together, our results establish a correlation between the clinical significance, immunosuppressive potential, and transcriptional network of well-defined neutrophil subsets, providing for the first time a set of optimal markers (CD11b/CD13/CD16) for accurate monitoring of G-MDSCs in MM.
引用
- Perez C, Botta C, Zabaleta A, et al. Immunogenomic identification and characterization of granulocytic myeloid-derived suppressor cells in multiple myeloma. Blood. 2020. PMID: 32325491. doi:10.1182/blood.2019004537
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。